Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy
Giulia Abate, Daniela Uberti, Simone Tambaro
Biology (2021) Vol. 10, Iss. 6, pp. 542-542
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Denisa Claudia Miculas, Paul Andrei Negru, Simona Bungău, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 131-131
Open Access | Times Cited: 45
Review: Cannabinoids as Medicinals
Jag Khalsa, Gregory Bunt, Kenneth Blum, et al.
Current Addiction Reports (2022) Vol. 9, Iss. 4, pp. 630-646
Open Access | Times Cited: 42
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1329-1329
Open Access | Times Cited: 37
The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer’s Disease-like Mouse Model
Juyong Kim, Pilju Choi, Young‐Tae Park, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6827-6827
Open Access | Times Cited: 28
Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer’s Disease
Jordan P. Hickey, Andrila E. Collins, Mackayla L. Nelson, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 5, pp. 4379-4402
Open Access | Times Cited: 9
Cannabidiol and brain function: current knowledge and future perspectives
Moniek Schouten, Sebastiaan Dalle, Dante Mantini, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 8
Mechanisms of comorbidity between Alzheimer's disease and pain
Kaifang Yao, Shenjun Wang, Zhifang Xu, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 1
Role of Terpenoids Active Ingredients Targeting for Neuroprotective Agents
Neelmani Kashyap, Roshan Kumar, Vinod Rana, et al.
Journal for Research in Applied Sciences and Biotechnology (2023) Vol. 2, Iss. 3, pp. 22-40
Open Access | Times Cited: 18
Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer’s Disease
Hina Kanwal, Moris Sangineto, Martina Ciarnelli, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 4050-4050
Open Access | Times Cited: 7
Opportunities, Challenges, and Scientific Progress in Hemp Crops
Kacper Piotr Kaminski, Julia Hoeng, Fernando Goffman, et al.
Molecules (2024) Vol. 29, Iss. 10, pp. 2397-2397
Open Access | Times Cited: 7
Endocannabinoid System Changes throughout Life: Implications and Therapeutic Potential for Autism, ADHD, and Alzheimer’s Disease
Kamila Gabrieli Dallabrida, Jeane Maria de Oliveira, Ellen Schavarski Chade, et al.
Brain Sciences (2024) Vol. 14, Iss. 6, pp. 592-592
Open Access | Times Cited: 6
Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer’s Disease
Parisa Faraji, Hartmut Kühn, Shahin Ahmadian
Journal of Molecular Neuroscience (2024) Vol. 74, Iss. 3
Open Access | Times Cited: 6
Δ8-THC Protects against Amyloid Beta Toxicity Modulating ER Stress In Vitro: A Transcriptomic Analysis
Agnese Gugliandolo, Santino Blando, Stefano Salamone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6598-6598
Open Access | Times Cited: 15
Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model
Philipp Spatz, Sophie A. M. Steinmüller, Anna Tutov, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 9, pp. 6414-6435
Open Access | Times Cited: 14
Wonder or evil?: Multifaceted health hazards and health benefits of Cannabis sativa and its phytochemicals
Shivika Datta, Praveen C. Ramamurthy, Uttpal Anand, et al.
Saudi Journal of Biological Sciences (2021) Vol. 28, Iss. 12, pp. 7290-7313
Open Access | Times Cited: 32
Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders
Álvaro Morcuende, María S. García‐Gutiérrez, Simone Tambaro, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 21
<b><i>Cannabis sativa</i></b> and Cannabidiol: A Therapeutic Strategy for the Treatment of Neurodegenerative Diseases?
Milena de Barros Viana, Pedro Everson Alexandre de Aquino, Débora Estadella, et al.
Medical Cannabis and Cannabinoids (2022) Vol. 5, Iss. 1, pp. 207-219
Open Access | Times Cited: 20
The Expression of the Endocannabinoid Receptors CB2 and GPR55 is Highly Increased during the Progression of Alzheimer’s Disease in AppNL-G-F Knock-In Mice
Dina Medina‐Vera, Hongjing Zhao, Erika Bereczki, et al.
Biology (2023) Vol. 12, Iss. 6, pp. 805-805
Open Access | Times Cited: 12
Local and long-range GABAergic circuits in hippocampal area CA1 and their link to Alzheimer’s disease
Melissa Hernández‐Frausto, Olesia M. Bilash, Arjun V. Masurkar, et al.
Frontiers in Neural Circuits (2023) Vol. 17
Open Access | Times Cited: 12
The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment
Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, et al.
BMC Complementary Medicine and Therapies (2025) Vol. 25, Iss. 1
Open Access
Chronic exposure to a synthetic cannabinoid improves cognition and increases locomotor activity in Tg4-42 Alzheimer's disease mice
Frederik Wilhelm Ott, Marius E. Sichler, Caroline Bouter, et al.
Journal of Alzheimer s Disease Reports (2025) Vol. 9
Open Access
Cannabinerol Restores mRNA Splicing Defects Induced by β-Amyloid in an In Vitro Model of Alzheimer’s Disease: A Transcriptomic Study
Maria Lui, Stefano Salamone, Federica Pollastro, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3113-3113
Open Access
The Major Hypotheses of Alzheimer’s Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment
César Cáceres, Bernardita Heusser, Alexandra L. Garnham, et al.
Cells (2023) Vol. 12, Iss. 23, pp. 2669-2669
Open Access | Times Cited: 10
Novel Dual-Acting Hybrids Targeting Type-2 Cannabinoid Receptors and Cholinesterase Activity Show Neuroprotective Effects In Vitro and Amelioration of Cognitive Impairment In Vivo
Claudia Mugnaini, Antonella Brizzi, Marco Paolino, et al.
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 5, pp. 955-971
Closed Access | Times Cited: 3
Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential
Barbara Vuić, Tina Milos, Lucija Tudor, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3000-3000
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top